Lymphoma, Non-Hodgkin: all 2,043 studies
Page 3 of 21. Open to participants first (309), then studies with results posted, then the rest; newest registration first within each.
- Modified TBF Regimen as Conditioning Regimen Prior to Allo-HSCT for T-ALL/LBLRecruitingNCT05598593Phase 2
- Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSLRecruitingNCT05583071Phase 2
- Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/LeukemiaRecruitingNCT05576532Phase 2
- Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHLRecruitingNCT05554939Phase 1/2
- Study of SGR-1505 in Mature B-Cell NeoplasmsRecruitingNCT05544019Phase 1
- Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) PatientsRecruitingNCT05529069Phase 2
- A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant TumorsRecruitingNCT05528055Phase 1
- B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021RecruitingNCT05518383Phase 4
- Clinical Study of the Efficacy of CD19-CAR-DNT Cells in the Treatment of Relapsed/Refractory B-cell NHLRecruitingNCT05453669Phase 1
- A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin LymphomaRecruitingNCT05444322Early Phase 1
- CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell MalignanciesRecruitingNCT05442515Phase 1/2
- Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's LymphomaRecruitingNCT05436223Phase 2
- Improving Communication and Building a Stronger Medical Home Among Spanish-speaking FamiliesRecruitingNCT05425992
- Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin LymphomaRecruitingNCT05420493Phase 1
- Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid MalignanciesRecruitingNCT05418088Phase 1
- Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated LymphomasRecruitingNCT05389423Phase 1
- A Mixed Methods Study of Nutrition Practice in Cancer Care on Non-Hodgkin Lymphoma PopulationRecruitingNCT05376709Not applicable
- Chidamide Bridging for CAR-T TherapyRecruitingNCT05370547Phase 1/2
- IKS03 in Patients With Advanced B Cell Non-Hodgkin LymphomasRecruitingNCT05365659Phase 1
- Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's LymphomaRecruitingNCT05338931Phase 1/2
- Long-Term Follow-up StudyEnrolling by invitationNCT05332054
- Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid TumorsRecruitingNCT05320640Phase 1/2
- Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin LymphomaRecruitingNCT05312801Phase 1
- Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-DegraderRecruitingNCT05294731Phase 1/2
- CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).RecruitingNCT05260957Phase 2
- A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)RecruitingNCT05254743Phase 3
- ADLs at the End of Acute Treatment for Childhood Leukemia and Non-Hodgkin LymphomaEnrolling by invitationNCT05235633
- APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin LymphomaRecruitingNCT05186012Phase 1/2
- A Phase Ia Clinical Study of QLF31907 Injection in Patients With Advanced Malignant TumorsRecruitingNCT05150405Phase 1
- CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell MalignanciesRecruitingNCT05105867Early Phase 1
- Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL PatientsRecruitingNCT05098613Phase 1
- In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PETRecruitingNCT05093335Early Phase 1
- A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's LymphomaNot yet recruitingNCT05091541Phase 1/2
- PET Adapted Treatment of Patients With Limited Stage DLBCL and no Risk FactorsRecruitingNCT05078840
- Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin LymphomaRecruitingNCT05077527Phase 1
- CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's LymphomaRecruitingNCT05054257Phase 1
- R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor BurdenRecruitingNCT05040555Not applicable
- Two Step Haplo With Radiation ConditioningRecruitingNCT05031897Phase 2
- A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell MalignanciesRecruitingNCT05006716Phase 1/2
- Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell TransplantationRecruitingNCT05005299Phase 1
- Evaluation of Lymphoma Prognosis and Survivorship in Recently Diagnosed Patients, LEO StudyEnrolling by invitationNCT04996706
- Faecal Microbiota Transplantation After Allogeneic Stem Cell TransplantationRecruitingNCT04935684Phase 2
- Methods of T Cell Depletion Trial (MoTD)RecruitingNCT04888741Phase 2
- Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell TherapyRecruitingNCT04870853
- Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid TumorsRecruitingNCT04851119Phase 1/2
- Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma PatientsRecruitingNCT04844866Phase 2
- DALY II USA/ MB-CART2019.1 for DLBCLRecruitingNCT04792489Phase 2
- Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.RecruitingNCT04771572Phase 1
- Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)RecruitingNCT04728893Phase 2
- A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's LymphomaRecruitingNCT04666168Not applicable
- EBV Specific T-Lymphocytes for Treatment of EBV-Positive LymphomaRecruitingNCT04664179Phase 1
- CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic DiseasesRecruitingNCT04662294Early Phase 1
- Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant DisordersRecruitingNCT04644016Phase 2
- CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's LymphomaNot yet recruitingNCT04609241Early Phase 1
- CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological MalignanciesRecruitingNCT04603872Early Phase 1
- Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's LymphomaRecruitingNCT04586478Phase 2
- Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin LymphomaRecruitingNCT04545762Phase 1
- A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological MalignanciesRecruitingNCT04532281Early Phase 1
- A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHLRecruitingNCT04532268Early Phase 1
- A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological MalignanciesRecruitingNCT04532203Early Phase 1
- A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHLRecruitingNCT04496349Phase 2
- Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a LymphomaRecruitingNCT04460235Phase 4
- Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) PatientsRecruitingNCT04440436Phase 1/2
- Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen ReceptorRecruitingNCT04337606Phase 1/2
- CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell MalignanciesRecruitingNCT04186520Phase 1/2
- A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasRecruitingNCT04104776Phase 1/2
- AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell DepletionRecruitingNCT04099966Phase 2
- Precision Exercise in Children With Malignant HemopathiesRecruitingNCT04090268Not applicable
- Study to Evaluate CCS1477 (Inobrodib) in Haematological MalignanciesRecruitingNCT04068597Phase 1/2
- Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell LymphomaRecruitingNCT04002947Phase 2
- A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With LBLRecruitingNCT03971318
- A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With Systemic ALK(+) ALCLRecruitingNCT03971305
- Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With BL/DLBCLRecruitingNCT03958916
- Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)RecruitingNCT03938987Phase 1/2
- CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic MalignanciesRecruitingNCT03765177Phase 1/2
- Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingNCT03666000Phase 1
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruitingNCT03452774
- CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)RecruitingNCT03328078Phase 1/2
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingNCT03297606Phase 2
- Leukapheresis for CAR or Adoptive Cell Therapy ManufacturingEnrolling by invitationNCT03226704
- Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaRecruitingNCT03223610Phase 1/2
- Non-Hodgkin Lymphoma - Observational Epidemiological and Clinical Study (NiHiL)RecruitingNCT03199066
- Auto Stem Cell Transplant for Lymphoma PatientsRecruitingNCT03125642Phase 2
- Expanded Access to VenetoclaxAvailableNCT03123029
- Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study IIIRecruitingNCT03117036
- Familial Investigations of Childhood Cancer PredispositionRecruitingNCT03050268
- Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma.RecruitingNCT02964858Not applicable
- CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)RecruitingNCT02917083Phase 1
- GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of Adult Acute Lymphoblastic Leukemia (ALL) Patients and Related Diseases Associated With a Prospective Collection of BiomaterialRecruitingNCT02872987
- ID Of Prognostic Factors In Mycosis Fungoides/Sezary SyndromeRecruitingNCT02848274
- Personalized NK Cell Therapy in CBTRecruitingNCT02727803Phase 2
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingNCT02693535Phase 2
- Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy ProtocolsRecruitingNCT02682667
- Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid TumorsRecruitingNCT02508038Phase 1
- Treatment of CIK for Patients With Refractory Non-Hodgkin LymphomaNot yet recruitingNCT02497898Phase 2
- Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHLRecruitingNCT02393157Phase 2
- CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive LymphomasRecruitingNCT02259556Phase 1/2
- The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative RegimenRecruitingNCT01890486
- Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)RecruitingNCT01853631Phase 1
- Tissue Collection for Studies of Lymph CancerRecruitingNCT01676805